You are here: Industry Insights > BNT162B2

News List

Pfizer, BioNTech Submit CMA for COVID-19 Vaccine americanpharmaceuticalreview
December 02, 2020
Pfizer and BioNTech have submitted a formal Application for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) for their mRNA vaccine candidate, BNT162b2, against COVID-19.
BioNTech, Fosun Pharma initiate Covid-19 vaccine candidate trial in China pharmaceutical-technology
November 27, 2020
BioNTech and Shanghai Fosun Pharmaceutical (Fosun Pharma) have initiated Phase II clinical trial of their lead mRNA Covid-19 vaccine candidate, BNT162b2, in Taizhou and Lianshui, Jiangsu Province, China.
Pfizer-BioNTech COVID-19 vaccine may create set of firsts for pharma sector: GlobalData expresspharma
November 23, 2020
In modern history, no vaccine has ever been considered as essential to restoring normality to our way of life as these first mRNA vaccines, says analyst.
Pfizer, BioNTech’s final Covid-19 vaccine study shows 95% efficacy pharmaceutical-technology
November 19, 2020
Pfizer and BioNTech have concluded the Phase III study of their mRNA-based Covid-19 vaccine candidate, BNT162b2, which showed 95% efficacy rate and met all primary efficacy endpoints.
Pfizer, BioNTech to Supply 200M Doses of BNT162b2 to EU contractpharma
November 12, 2020
Deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.
Pfizer, BioNTech Announce COVID-19 Vaccine Demonstrates Efficacy in Phase 3 Analysis americanpharmaceuticalreview
November 11, 2020
Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy ...
Pfizer, BioNTech COVID-19 Vax Candidate Successful in Phase III Interim Analysis contractpharma
November 10, 2020
mRNA-based vaccine candidate BNT162b2 found to be more than 90% effective in preventing COVID-19.
EMA begins rolling review of BNT162b2 COVID-19 vaccine europeanpharmaceuticalreview
October 16, 2020
The rolling review of BNT162b2 will allow the committee for human medicines (CHMP) to reach a faster decision on a future marketing authorisation application.
Pfizer and BioNTech initiate rolling submission for Covid-19 vaccine pharmaceutical-technology
October 10, 2020
Pfizer and BioNTech have initiated a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the vaccine candidate against Covid-19.

Previous page 1 2 3 Next page